# OnCo record extrapulmonary-nec (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/extrapulmonary-nec/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "extrapulmonary-nec" ;
  schema:name "Extrapulmonary neuroendocrine carcinoma"@en ;
  schema:alternateName "Extrapulmonary NEC"@en, "Gastroenteropancreatic neuroendocrine carcinoma"@en, "GEP-NEC"@en, "Extrapulmonary small-cell carcinoma"@en, "Large-cell neuroendocrine carcinoma of the gut"@en, "Poorly differentiated neuroendocrine carcinoma"@en ;
  schema:description "Extrapulmonary neuroendocrine carcinoma is the fast-growing, poorly differentiated form of neuroendocrine cancer arising outside the lung, most often in the bowel, oesophagus, stomach or pancreas. It behaves like small-cell lung cancer and is treated the same way, with platinum and etoposide chemotherapy, and drugs against the DLL3 protein are now in phase 3 trials."@en ;
  schema:url <https://onco.cc/cancers/extrapulmonary-nec/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  schema:citation <https://doi.org/10.1093/annonc/mds276>, <https://doi.org/10.1158/1078-0432.CCR-19-3356>, <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  onco:tag "subtype-page", "endocrine" ;
  onco:technologies <https://onco.cc/technologies/pet/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/peluntamig/>, <https://onco.cc/drugs/zg006/>, <https://onco.cc/drugs/obrixtamig/> ;
  onco:pathways <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/> ;
  onco:terms <https://onco.cc/terms/net-grade-ki67/>, <https://onco.cc/terms/tumour-differentiation/>, <https://onco.cc/terms/histologic-transformation/> ;
  onco:trials <https://onco.cc/trials/dart-s1609/>, <https://onco.cc/trials/nct07544654/>, <https://onco.cc/trials/nct05882058/>, <https://onco.cc/trials/nct05652686/> ;
  onco:pipeline <https://onco.cc/trials/nct07544654/>, <https://onco.cc/trials/nct05882058/>, <https://onco.cc/trials/nct05652686/>, <https://onco.cc/drugs/peluntamig/>, <https://onco.cc/drugs/zg006/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/targets/dll3/>, <https://onco.cc/trials/dart-s1609/>, <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/> ;
  onco:standardOfCare <https://onco.cc/terms/net-grade-ki67/>, <https://onco.cc/terms/tumour-differentiation/>, <https://onco.cc/technologies/pet/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/sstr-pet/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/dart-s1609/>, <https://onco.cc/trials/nct07544654/>, <https://onco.cc/trials/nct05882058/>, <https://onco.cc/targets/dll3/>, <https://onco.cc/terms/net-grade-ki67/>, <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/drugs/lutathera/> .